We're working on something new at CrunchBase. Edits have been disabled for a few days, but you can still contact us for urgent changes.
Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Funding

VENTURE FUNDING
Venture Round, 1/2013
Troika Dialog

Tags

StemPar Sciences

StemPar is developing a pipeline of powerful, first-in-class cancer drugs that attack solid tumors by simultaneously disrupting their source of energy and defensive ability to hijack the body’s DNA-repair mechanism to regenerate when under assault. The scientific premise of this so-called cancer metabolism strategy has been studied for generations–and earned the scientist who discovered it a Nobel Prize–but it is only recently that scientists figured out how to crack the code of cancer metabolism sufficiently to build a commercially viable drug development effort around it. Their scientists are at the forefront of this effort and thier leadership team has long been at the forefront of transforming breakthrough scientific discoveries into life-saving medicines. StemPar cofounder and CEO Barry Sherman, MD played a pivotal role in the development of some of the most important cancer medicines in their generation (Herceptin, Rituxan) and in the process helped build the most successful biotech in history (Genentech).

Recent Milestones

Videos

Screenshots

StemPar Sciences screenshot
Above: StemPar Sciences
Uploaded: 1/4/13

Sources

  1. StemPar Sciences Secures Initial Funding For Its Novel Cancer Metabolism Drugs (in.finance.yahoo.com) [edit]
Edit This Page
Last Edited 4/16/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy